The Asia Pacific Omics Lab Services Market would witness market growth of 13.4% CAGR during the forecast period (2022-2028).
RNA sequencing uses next-generation sequencing to analyze the amount and sequences of RNA in a sample. Additionally, the Microarray method can simultaneously identify the expression of genes in hundreds of samples. Each transcript in a sample is recognized by RNA sequencing, while microarrays employ hybridization to only identify pre-selected transcripts or genes. The polymerase chain reaction technique is used to make different copies of a single gene in order to recognize and examine a brief sequence of RNA or DNA. Additionally, these techniques allow researchers to examine disorders at the genomic level. Additionally, it helps with the creation of fresh clinical biomarkers, the detection of several molecular diseases, and the analysis of different drugs.
Researchers are working on projects in a range of cutting-edge sectors in laboratories all around the globe that have the potential to shed fresh light on human health and illness. Such "omics" domains also provide prospects for developing enhanced diagnostics that will fulfill the increasing demands of a healthcare industry centered on the pursuit of precision and customized treatment. They build upon and add to the insights obtained by the Human Genome Project.
As more genomics technologies are accepted and discovered in emerging nations like China and India for the treatment, diagnosis, and prognosis of numerous genetic disorders, including cancer and diabetes, the market is anticipated to grow. Additionally, the rising prevalence of chronic illnesses, including diabetes, rheumatoid arthritis, cancer, Alzheimer's disease, and other neurological disorders, might be linked to the region's expansion.
The Diagnostic Labs market dominated the Asia Pacific Omics Lab Services Market by Business in 2021; thereby, achieving a market value of $18.8 billion by 2028. The Research Institutes market is poised to grow at a CAGR of 13.7% during (2022 - 2028). Additionally, The Hospitals market would exhibit a CAGR of 13.9% during (2022 - 2028).
Based on Business, the market is segmented into Diagnostic Labs, Research Institutes, and Hospitals. Based on End Use, the market is segmented into Cancer, Pharmaco, Population Studies & Genealogy, Reproductive, Skincare, Nutrition, Vitamin & Supplements, and Forensics & Others. Based on Type, the market is segmented into Proteomics, Transcriptomic, Metabolomics, Genomics, and Epigenetics. Based on Product, the market is segmented into Hardware Equipment, Testing / Lab Services, and Analytics / Interpretation. Based on Frequency of Service, the market is segmented into Continuous, Repeat, and One-off. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Omics Lab Services Market is Projected to reach USD 139.1 Billion by 2028, at a CAGR of 12.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Illumina, Inc., BGI Group, Q2 Solutions (IQVIA), Flomics Biotech, PhenoSwitch Bioscience
By Business
By End-Use
By Type
By Product
By Frequency of Service
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
